Peptide
Contacts
供应商
肽类
专家
研究
学习
社区
新闻
工具
Search...
⌘K
登录
注册
打开菜单
FDA
FDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibility
UPDATE
Semaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025
REGULATORY
12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC review
REGULATORY
No formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027
RESEARCH
A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]
RESEARCH
Study to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]
RESEARCH
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]
RESEARCH
A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]
RESEARCH
Hypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]
RESEARCH
Effects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]
NEWS
STAT+: Peptide market poised to explode with new Hims and Noom launches
RESEARCH
Alleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]
RESEARCH
Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]
RESEARCH
SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]
FDA
FDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibility
UPDATE
Semaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025
REGULATORY
12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC review
REGULATORY
No formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027
RESEARCH
A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]
RESEARCH
Study to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]
RESEARCH
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]
RESEARCH
A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]
RESEARCH
Hypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]
RESEARCH
Effects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]
NEWS
STAT+: Peptide market poised to explode with new Hims and Noom launches
RESEARCH
Alleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]
RESEARCH
Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]
RESEARCH
SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]
仅供研究使用。
完整免责声明 →
全部联系人
Researcher
Loren Cordain
Colorado State University
W
关于我们
Loren Cordain (born October 24, 1950) is an American scientist who specializes in the fields of nutrition and exercise physiology. He is notable as an advocate of the Paleolithic diet.